Protein dynamics associated with failed and rescued learning in the ts65dn mouse model of down syndrome

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Ahmed, Md Mahiuddin ^a   Dhanasekaran, A Ranjitha ^a   Block, Aaron ^a   Tong, Suhong ^b   Costa, Alberto C S ^c   Stasko, Melissa ^c   Gardiner, Katheleen J ^a,d,e  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b Food Science and Human Nutrition   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAIN DERIVED NEUROTROPHIC FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE 5; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE RECEPTOR 4; GLYCOGEN SYNTHASE KINASE 3BETA; INITIATION FACTOR 4B; INTERLEUKIN 1BETA; MAMMALIAN TARGET OF RAPAMYCIN; MEMANTINE; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; NEURONAL NITRIC OXIDE SYNTHASE; PROTEIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; PROTEIN KINASE FYN; PROTEIN S6; PROTEIN TYROSINE KINASE A; RECEPTOR SUBUNIT; TAU PROTEIN; UBIQUITIN; PROTEIN SUBUNIT; PROTEOME;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONDITIONING; CONTEXT FEAR CONDITIONING; CONTROLLED STUDY; DOWN SYNDROME; FAILED LEARNING; FEMALE; HIPPOCAMPUS; LEARNING; MALE; MOUSE; MOUSE MODEL; MOUSE STRAIN; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; RESCUED LEARNING; TS65DN MOUSE; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; PROCEDURES; PROTEIN SUBUNIT; PROTEOMICS;

MUS;

ANIMALS; DISEASE MODELS, ANIMAL; DOWN SYNDROME; LEARNING; MEMANTINE; MICE; PROTEIN SUBUNITS; PROTEOME; PROTEOMICS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84925678088     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119491     Document Type: Article

References (51)

1. Irving C, Basu A, Richmond S, Burn J, Wren C. Twenty-year trends in prevalence and survival of Down syndrome. Eur J Hum Genet. 2008; 16: 1336-1340. doi: 10.1038/ejhg.2008.122 PMID: 18596694
2. CDC, Centers for Disease Control and Prevention. Improved National Prevalence for 18 Major Birth Defects. MMWR 2006; 54: 6-12.
3. Chapman RS, Hesketh LJ. Behavioral phenotype of individuals with Down syndrome. Ment Retard Dev Disabil Res Rev. 2000; 6: 84-95. PMID: 10899801
4. Silverman W. Down syndrome: cognitive phenotype. Ment Retard Dev Disabil Res Rev. 2007; 13: 228-236. PMID: 17910084
5. Sturgeon X, Gardiner KJ. Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mam Genome 2011; 22: 261-271.
6. Rahmani Z, Blouin JL, Créau-Goldberg N, Watkins PC, Mattei JF, Poisonnier M, et al. Down syndrome critical region around D21S55 on proximal 21q22.3. Am J Med Genet. 1990;Suppl 7: 98-103.
7. Korenberg JR, Chen XN, Schipper R, Sun Z, Gonsky R, Gerwehr S, et al. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc Natl Acad Sci USA 1994; 91: 4997-5001. PMID: 8197171
8. Korbel JO, Tirosh-Wagner T, Urban AE, Chen XN, Kasowski M, Grubert F, et al. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc Natl Acad Sci USA 2009; 106: 12031-12036. doi: 10.1073/pnas.0813248106 PMID: 19597142
9. Davisson MT, Schmidt C, Reeves RH, Irving NG, Akeson EC, Harris BS, et al. Segmental trisomy as a mouse model for Down syndrome. Prog Clin Biol Res. 1993; 384: 117-133. PMID: 8115398
10. Rueda N, Flórez J, Martínez-Cué C. Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast. 2012: 584071. doi: 10.1155/2012/584071 PMID: 22685678
11. Duchon A, Raveau M, Chevalier C, Nalesso V, Sharp AJ, Herault Y. Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome. Mamm Genome 2011; 22: 674-684. doi: 10.1007/s00335-011-9356-0 PMID: 21953411
12. Ahmed MM, Dhanasekaran AR, Tong S, Wiseman FK, Fisher EM, Tybulewicz VL. Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain. Hum Mol Genet. 2013; 22: 1709-1724. doi: 10.1093/hmg/ddt017 PMID: 23349361
13. Gardiner KJ. Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations. Drug Design Devel Ther. 2014; 9:103-125.
14. Braudeau J, Delatour B, Duchon A, Lopes-Pereira P, Dauphinot L, de Chaumont F, et al. Specific targeting of the GABA-A receptor {alpha}5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J Psychopharmacol. 2011; 25: 1030-1042. doi: 10.1177/0269881111405366 PMID: 21693554
15. Martínez-Cué C, Martínez P, Rueda N, Vidal R, García S, Vidal V, et al. Reducing GABAA α5 receptormediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome. J Neurosci. 2013; 33: 3953-3966. doi: 10.1523/JNEUROSCI.1203-12.2013 PMID: 23447605
16. Costa AC, Scott-McKean JJ, Stasko MR. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 2008; 33: 1624-1632. PMID: 17700645
17. Chang Q, Gold PE. Age-related changes in memory and in acetylcholine functions in the hippocampus in the Ts65Dn mouse, a model of Down syndrome. Neurobiol Learn Mem. 2008; 89: 167-177. PMID: 17644430
18. Corrales A, Martínez P, García S, Vidal V, García E, Flórez J, et al. Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in mid-dle-aged Ts65Dn mice, a model of Down syndrome. J Pineal Res. 2013; 54: 346-358. doi: 10.1111/jpi.12037 PMID: 23350971
19. Das I, Park JM, Shin JH, Jeon SK, Lorenzi H, Linden DJ, et al. Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model. Sci Transl Med. 2013; 5: 201ra120.doi: 10.1126/scitranslmed.3005983 PMID: 24005160
20. Busciglio J, Capone G, O'Bryan J, Gardiner KJ. Down syndrome: genes, model systems, and progress towards pharmacotherapies and clinical trials for cognitive deficits. Cytogenet Genome Res. 2013; 141: 260-271. doi: 10.1159/000354306 PMID: 24008277
21. Gardiner KJ. Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends Pharmacol Sciences 2010; 31: 66-73. doi: 10.1016/j.tips.2009.10.010 PMID: 19963286
22. Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebocontrolled trial. Lancet 2012; 379: 528-536. doi: 10.1016/S0140-6736(11)61676-0 PMID: 22236802
23. Boada R, Hutaff-Lee C, Schrader A, Weitzenkamp D, Benke TA, Goldson EJ, et al. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry 2012; 2: e141. doi: 10.1038/tp.2012.66 PMID: 22806212
24. De la Torre R, De Sola S, Pons M, Duchon A, de Lagran MM, Farre M, et al. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol Nutr Food Res. 2014; 58: 278-288. doi: 10.1002/mnfr.201300325 PMID: 24039182
25. Chen HS, Lipton SA. Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels. J Pharmacol Ex. Ther. 2005; 314: 961-971 PMID: 15901795
26. Lipton SA. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets 2007; 8: 621-632. PMID: 17504105
27. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 1999; 38: 735-767.PMID: 10465680
28. Rothermel BA, Vega RB, Williams RS. The role of modulatory calcineurin-interacting proteins in calcineurin signaling. Trends Cardiovasc Med. 2003; 13: 15-21. PMID: 12554096
29. Lieberman DN, Mody I. Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. Nature 1994; 369: 235-239. PMID: 7514273
30. Siddiqui A, Lacroix T, Stasco MR, Scott-Mckean JJ, Costa AC, Gardiner KJ. Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801. Genes Brain Behav. 2008; 7: 810-819. doi: 10.1111/j.1601-183X.2008.00428.x PMID: 19125866
31. Jung MS, Park JH, Ryu YS, Choi SH, Yoon SH, Kwen MY, et al. Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation. J Biol Chem. 2011; 286: 40401-40412. doi: 10.1074/jbc. M111.253971 PMID: 21965663
32. Putkey JA, Kleerekoper Q, Gaertner TR, Waxham MN. A new role for IQ motif proteins in regulating calmodulin function. J Biol Chem. 2003; 278: 49667-49670. PMID: 14551202
33. Nishimura T, Yamaguchi T, Tokunaga A, Hara A, Hamaguchi T, Kato K, et al. Role of numb in dendritic spine development with a Cdc42 GEF intersectin and EphB2. Mol Biol Cell 2006; 17: 1273-1285.PMID: 16394100
34. Tolias KF, Bikoff JB, Burette A, Paradis S, Harrar D, Tavazoie S, et al. The Rac1-GEF Tiam1 couples the NMDA receptor to the activity-dependent development of dendritic arbors and spines. Neuron 2005; 45: 525-538. PMID: 15721239
35. Snyder EM, Non Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005; 8: 1051-1058. PMID: 16025111
36. Rueda N, Llorens-Martín M, Flórez J, Valdizán E, Banerjee P, Trejo JL, et al. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J Alzheimers Dis. 2010; 21: 277-290. doi: 10.3233/JAD-2010-100240 PMID: 20421694
37. Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res. 2011; 221: 610-622.doi: 10.1016/j.bbr.2010.03.036 PMID: 20363261
38. Scott-McKean JJ, Costa AC. Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. Learn Mem. 2011; 18: 774-778. doi: 10.1101/lm. 024182.111 PMID: 22101180
39. Ahmed MM, Dhanasekaran AR, Block A, Tong S, Costa AC, Gardiner KJ. Protein profiles associated with context fear conditioning and their modulation by memantine. Mol Cell Proteomics 2014; 13: 919-937. doi: 10.1074/mcp.M113.035568 PMID: 24469516
40. Costa AC, Stasko MR, Schmidt C, Davisson MT. Behavioral validation of the Ts65Dn mouse model for Down syndrome of a genetic background free of the retinal degeneration mutation Pde6b(rd1) Behav Brain Res. 2010; 206: 52-62. doi: 10.1016/j.bbr.2009.08.034 PMID: 19720087
41. Liu DP, Schmidt C, Billings T, Davisson MT. Quantitative PCR genotyping assay for the Ts65Dn mouse model of Down syndrome. Biotechniques 2003; 35: 1170-1174. PMID: 14682051
42. Radulovic J, Rühmann A, Liepold T, Spiess J. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci. 1999; 19: 5016-5025. PMID: 10366634
43. Ahmed MM, Sturgeon X, Ellison M, Davisson MT, Gardiner KJ. Loss of correlations among proteins in brains of the Ts65Dn mouse model of down syndrome. J Proteome Res. 2012; 11: 1251-1263. doi: 10. 1021/pr2011582 PMID: 22214338
44. Sturgeon X, Le T, Ahmed MM, Gardiner KJ. Pathways to cognitive deficits in Down syndrome. Prog Brain Res. 2012; 197: 73-100. doi: 10.1016/B978-0-444-54299-1.00005-4 PMID: 22541289
45. García-Cerro S, Martínez P, Vidal V, Corrales A, Flórez J. Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome. PLoS One 2014; 9: e106572. doi: 10.1371/journal.pone.0106572 PMID: 25188425
46. Vilardell M, Rasche A, Thormann A, Maschke-Dutz E, Pérez-Jurado LA, Lehrach H, et al. Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes. BMC Genomics 2011; 12: 229. doi: 10.1186/1471-2164-12-229 PMID: 21569303
47. Krzywinski M, Altman N. Points of significance: Comparing samples-part II. Nat Methods 2014; 11: 355-356.
48. Rozeske RR, Valerio S, Chaudun F, Herry C. Prefrontal neuronal circuits of contextual fear conditioning. Genes Brain Behav. 2015; 14(1): 22-36. doi: 10.1111/gbb.12181 PMID: 25287656
49. Contestabile A, Greco B, Ghezzi D, Tucci V, Benfenati F, Gasparini L. Lithium rescues synaptic plasticity and memory in Down syndrome mice. J Clin Invest. 2013; 123: 348-361. doi: 10.1172/JCI64650PMID: 23202733
50. Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, et al. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci. 2012; 32: 9217-9227. doi: 10.1523/JNEUROSCI.1673-12.2012 PMID: 22764230
51. Yang X, Schadt EE, Wang S, Wang H, Arnold AP, Ingram-Drake L, et al. Tissue-specific expression and regulation of sexually dimorphic genes in mice. Genome Res. 2006; 16: 995-1004. PMID: 16825664